NATIONAL HARBOR, Md.—Black hemodialysis (HD) patients with anemia require relatively more epoetin than their non-black counterparts to achieve similar hemoglobin (Hb) levels, but blacks and non-blacks required similar peginesatide doses, according to findings presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Rapid anemia management (RAM) for patients with end-stage renal disease within seven days of hospital discharge decreases their rate of readmission, according to findings presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Nearly two thirds of patients with end-stage renal disease (ESRD) experience a drop in hemoglobin (Hb) level after hospitalization, and it may take months after hospitalization for Hb levels to recover, researchers reported at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Researchers have found that hemoglobin levels in dialysis patients have changed since implementation of the bundled payment system for dialysis services in January 2011, according to a report presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—In a recently completed clinical trial, treatment with ferumoxytol resulted in a greater hemoglobin (Hb) response than iron sucrose in hemodialysis (HD) patients with anemia and non-dialysis patients with severe anemia, researchers reported at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Hemodialysis (HD) patients receiving either epoetin or peginesatide who achieve low hemoglobin (Hb) levels have an increased rate of cardiovascular (CV) events, according to new data presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
Please login or register first to view this content.
